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ABSTRACT 
Background Thoracic aortic aneurysm / dissection (TAAD) is a common phenotype that may 
occur as an isolated manifestation or within the constellation of a defined syndrome. In 
contrast to syndromic TAAD, the elucidation of the genetic basis of isolated TAAD has only 
recently started. To date, defects have been found in genes encoding extracellular matrix 
proteins (fibrillin-1, FBN1; collagen type III alpha 1, COL3A1), proteins involved in 
transforming growth factor beta (TGFβ) signaling (TGFβ receptor 1 and 2, TGFBR1/2; and 
SMAD3) or proteins that build up the contractile apparatus of aortic smooth muscle cells 
(myosin heavy chain 11, MYH11; smooth muscle actin alpha 2, ACTA2; and MYLK). 
Methods and results In 110 non-syndromic TAAD patients that previously tested negative 
for FBN1 or TGFBR1/2 mutations, we identified 7 ACTA2 mutations in a cohort of 43 
familial TAAD patients, including 2 premature truncating mutations. Sequencing of MYH11 
revealed an in frame splice-site alteration in one out of two probands with TAA(D) associated 
with PDA but none in the series of 22 probands from the cohort of 110 patients with non-
syndromic TAAD. Interestingly, immunohistochemical staining of aortic biopsies of a patient 
and a family member with MYH11 and patients with ACTA2 missense mutations showed 
upregulation of the TGFβ signaling pathway. 
Conclusions MYH11 mutations are rare and typically identified in patients with TAAD 
associated with PDA. ACTA2 mutations were identified in 16% of a cohort presenting familial 
TAAD. Different molecular defects in TAAD may account for a different pathogenic 
mechanism of enhanced TGFβ signaling.  
 




Aortic aneurysms and dissections are a frequent cause of morbidity and mortality in 
the Western world [1, 2]. In thoracic aortic aneurysms and dissections (TAAD), the dilatation 
most commonly involves the aortic root and/or ascending aorta. Dissections are mostly of the 
Stanford type A, involving the ascending aorta, Stanford type B dissections (occurring distally 
from the subclavian artery) are less common. TAAD may occur within the context of defined 
monogenic syndromes, in particular the Marfan syndrome (MFS). More commonly, TAAD 
presents in the absence of a clear syndromic constellation, i.e. non-syndromic TAAD. In up to 
20% of TAAD patients a positive family history is observed, clearly indicating a genetic 
contribution in the etiology [3]. 
The search for the underlying molecular defect in non-syndromic TAAD has 
confirmed the genetic heterogeneity of the syndrome and has increased our insights into the 
complex pathophysiology of aneurysm formation. Occasionally mutations in FBN1 and 
TGFBR1/2 have been documented [4] in patients presenting either mild connective tissue 
manifestations or widespread vascular disease. As such, these patients may represent variable 
expression of MFS or Loeys-Dietz syndrome (LDS). Three loci for TAAD have been 
mapped, but the causal gene has not been identified yet. One locus was mapped to 5q13-14 in 
nine out of fifteen families with autosomal dominantly segregating TAAD with reduced 
penetrance [5]; a second locus on 11q23-24 was identified in a single, large family 
characterized by a diffuse vascular disease, designated as FAA [6]. The third locus was 
recently identified by Guo and colleagues, the locus, TAAD5, was mapped to chromosome 12 
(19,5-68,1 Mb) [7]. The family in which this locus was identified is characterized by stable 
ascending aortic aneurysm with a low risk of dissection and a marked decreased penetrance in 
females. 
Four novel gene defects have been reported in the context of TAAD. First, mutations 
in myosin heavy chain protein 11 (MYH11), a specific contractile protein of smooth muscle 
cells, have been identified in 2 families with dominant transmission of TAAD in conjunction 
with patent ductus arteriosus (PDA) [8]. In another study, in which 2 additional MYH11 
mutations were found, it was shown that a structural defect in MYH11 disturbs contractile 
smooth muscle cell function and leads to lower aortic compliance and elastolysis as well as 
focal vascular smooth muscle hyperplasia [9]. Second, mutations in ACTA2 (encoding the 
smooth muscle cytoskeletal protein actin α2) were identified in families with aortic root 
dilatation and a variety of associated manifestations, including patent ductus arteriosus 
(PDA), bicuspid aortic valve (BAV), iris flocculi, livedo reticularis, cerebrovascular accident 
(CVA) and stenosis of the aortic vasa vasorum [10]. In addition TAAD caused by ACTA2 
mutations is occasionally combined with premature onset of coronary artery disease, stroke 
and Moya-Moya disease [11]. Recently, 5 new papers were published, all identifying new 
and/or previously published ACTA2 mutations in TAAD patients with a variable association 
of extravascular traits [12-16]. These findings make this gene defect the most common cause 
of familial TAAD identified to date. Third, mutations were recently identified in the gene 
encoding myosin light chain kinase (MYLK), a kinase that is involved in smooth muscle cell 
contractility. The mutations found so far have an effect on kinase activity or calmodulin 
binding properties of the protein, clinically leading to acute aortic dissection with minimal or 
no aortic enlargement prior to dissection [17]. The most recently identified gene in the context 
of TAAD is the SMAD3 gene, which is a member of the TGFβ pathway that is essential for 
TGFβ signal transmission. Patients harboring SMAD3 mutations display a phenotype mainly 
characterized by ascending aortic aneurysm and dissection in association with early onset 
osteoarthritis [18].  
The identification of MYH11, ACTA2 and MYLK gene mutations confirm the 
importance of the smooth muscle cell contractile apparatus in maintaining the structural 
integrity of the ascending aorta, but the precise pathophysiological mechanism underlying the 
development of aneurysms remains unclear [10]. 
We screened a large cohort of TAAD patients in whom FBN1 and TGFBR1/2 were 
excluded, for both ACTA2 and MYH11 to further delineate the associated phenotypes. We also 
assessed the involvement of the TGFβ pathway using dedicated staining methods. We 
identified one novel MYH11 mutation, and 5 novel and 2 previously identified ACTA2 
mutations and provide evidence that enhanced TGFβ signaling contributes to the 
pathophysiology of aneurysms associated with MYH11 mutations and ACTA2 missense 
mutations. 
 
2. Material and methods 
2.1 Patients and samples 
The cohort consisted of 110 probands from Europe and the United States of America. 
All probands were evaluated by a clinical geneticist at the referring center. Clinical 
information was obtained by means of a detailed checklist. All patients screened had an 
ascending aortic aneurysm (Z-score > 3) either at the sinuses of Valsalva or the more distal 
part of the ascending aorta, and neither fulfilled the diagnostic criteria for MFS [19] or 
presented with a syndromic form of TAAD. All patients tested negative for FBN1 and 
TGFBR1/2 by sequencing. Family history of TAAD was present in 43 of the 110 probands. 
All 110 probands were screened for ACTA2 mutations and a randomly limited set of 22 
probands was screened for MYH11. In addition, we screened the MYH11 gene in two patients 
associating TAAD associated with PDA, who were not included in the cohort of 110 
probands. Mutation-positive families were clinically re-evaluated by the referring clinician.  
Genomic DNA was extracted from peripheral blood and/or cultured skin fibroblasts. 
Skin fibroblasts were cultured in Dulbecco’s modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) in the presence of antibiotics and 
antimycotics. Aortic specimens were obtained at the occasion of aortic root replacement. 
Aortic tissues were available from family 1 member II:3, family 2 member III:3, family 4 
member II:4, and family 8 member III:1 and III:6 (Figure 2). Aortic tissue from control 
patients who died of unrelated causes was obtained during autopsy. This study was approved 
by the ethics committee of the Ghent University Hospital and all referring centers, and an 
appropriate informed consent was obtained from all patients involved in the study. 
 
2.2 Molecular analysis 
Genomic DNA was amplified by touchdown PCR of all coding exons with their exon-
intron boundaries of ACTA2 and MYH11, respectively, using forward and reverse primers 
located in the flanking introns (primer sequences available upon request). The PCR products 
were analyzed by gel electrophoresis and visualized by ethidium bromide staining on 2% 
agarose gels. All amplimers were directly sequenced on the ABI PRISM 3730 automated 
sequencer (Applied Biosystems) using the BigDye terminator cycle sequencing chemistry. 
These sequences were compared to the wild-type sequence as submitted to GenBank 
Accession number NM_022844.2 and NM_002474 of MYH11 and ACTA2, respectively. All 
mutations were confirmed to be segregating with the phenotype and found absent in a panel of 
100 normal control individuals.  
 
2.3 Staining of aortic sections 
Formalin-fixed and paraffin-embedded aortic tissue was cut in 5 µm sections and 
prepared for immunohistochemical analysis. Sections were stained for phospho-Smad2 (Cell 
Signaling Technologies) and CTGF (Abcam). Briefly, antigens were unmasked using 1mM 
EDTA pH 8 and auto-peroxidase activity was inhibited. Sections were blocked with normal 
goat serum (Vectastain) and incubated with antibodies directed against CTGF and pSmad2 
(Ser465/467). Subsequently, sections were incubated with a secondary antibody goat-anti-
rabbit IgG (Vectastain), ABC (Avidin: Biotinylated enzyme Complex) reagent (Vectastain) 
and DAB (3,3'-Diaminobenzidine) peroxidase (Vectastain). Sections were dehydrated in 
xylene and mounted. Additionally, immunofluorescent co-staining for fibronectin-1 (FN1) 
and smooth muscle α-actin was performed. Sections were deparaffinized, rehydrated, blocked 
with 5% bovine serum albumin (BSA, Sigma Aldrich), and subsequently incubated with 
primary antibodies directed against FN1 (Abcam) and smooth muscle α-actin (Sigma 
Aldrich). Next, the sections were incubated with secondary antibodies, donkey anti-rabbit 
alexa 488 (Invitrogen) and goat anti-mouse Cy3 (GE Healthcare), respectively. Finally, the 




3.1 Genomic sequencing of MYH11 and ACTA2 
In 110 consecutive patients with TAAD, of which 43 familial cases and 67 isolated 
cases, ACTA2 mutations were identified in 7 probands, all with a positive family history of 
TAAD. In family 1 and 2 we identified mutations that result in a premature termination 
codon: c.940C>T; p.Arg314X (family 1) and c.1019_1020delCT; p.Ser340Cys fs X25 (family 
2). In families 3-7, five ACTA2 missense substitutions (c.124C>A; p.His42Asn, c.115C>T; 
p.Arg39Cys, c.145G>A; p.Met49Val, c.112G>A; p.Gly38Arg, and c.182A>G; p.Gln61Arg, 
respectively) were identified, of which 3 are novel (p.His42Asn, p.Gly38Arg, and 
p.Gln61Arg) and the latter two were previously reported (p.Arg39Cys and p.Met49Val) [13]. 
See Figure 1. No ACTA2 mutations were found in the 67 sporadic TAAD patients. 
In 2 families with TAAD associated with PDA, a causal aberration in MYH11 was found in 
one family (family 8): IVS32+1G>A mutation in intron 32 (Figure 1). In contrast, no MYH11 
mutation was found in a series of 22 patients with non-syndromic FTAAD.  
 
3.2 Clinical phenotypes 
Family 1 
The 70-year-old female proband presented at the emergency department with acute 
type A aortic dissection and died during surgery. Autopsy revealed no other dysmorphic 
features. The type A dissection originated in an aortic root aneurysm of 50 mm and stretched 
down into the descending aorta. Section of the coronary arteries revealed a distal stenosis of 
75% of the left anterior descending artery. The proband’s mother had died suddenly at the age 
of 63 and the proband’s father had a fatal cerebrovascular accident at age 77.  The proband’s 
brother underwent aortic root replacement at the age of 45. At the age of 65, he required 
revision because of partial detachment of the distal suture between the prosthesis and the aorta 
with formation of a pseudoaneurysm. Because of this family history, the three children of the 
proband (respectively aged 48, 47 and 45 years) were referred to the genetics department for 
further assessment. Both daughters presented normal echocardiographic findings, whereas the 
47-year-old son presented mild dilatation of the aortic root at the sinuses of Valsalva (42 mm, 
Z=2.03). Subsequent screening of his children revealed mild aortic dilatation in the 21-year-
old daughter (38 mm at the sinuses of Valsalva, Z=2.9). None of the affected family members 
presented dysmorphic features, connective tissue abnormalities, skin manifestations or other 
vascular involvement at the time of evaluation. 
 
Family 2  
The currently 84-year-old male proband presented to the clinic at the age of 68 years 
with a type B aortic dissection for which he was successfully stented. He did not present any 
clinical features reminiscent of MFS or LDS. His parents died at old age and not due to aortic 
aneurysm. His paternal aunt died in her late thirties during surgery for a ruptured abdominal 
aneurysm. His 40-year old son has borderline aortic root measurements – the mutation was 
excluded in him. A paternal cousin of the proband required aortic root replacement for 
aneurysm formation associated with valvular insufficiency at the age of 56. He died at age 70 
of a ruptured abdominal aortic aneurysm.  
 
Family 3  
The 32-year-old male proband was diagnosed with an aortic root aneurysm and 
associated aortic valve insufficiency. He did not have any clinical signs of a connective tissue 
disorder. His mother died suddenly of a type A aortic dissection at the age of 48. His maternal 
aunt and her 32-year-old son also died from aortic dissection. The family was lost for further 
follow-up. 
 
Family 4   
The 47-year-old male proband is the third child of non-consanguineous parents. At the 
age of 32, he required an emergency Bentall procedure for a type A aortic dissection. Follow-
up CT-angiography at the age of 36 revealed a dilatation of the aorta distal from the prosthesis 
with a maximal diameter of 50 mm, a saccular aneurysm of the descending thoracic aorta of 
38 mm (from the level of the left atrium to the diaphragm) with a chronic dissection in the 
most distal 1.5 cm and an infrarenal aortic aneurysm of 37 mm, extending to the iliac 
bifurcation, with a mural thrombus. Arteriography of the coronary and cerebral arteries was 
normal. The 22-year-old son of the proband showed borderline aortic diameters on 
echocardiography (36 mm at the sinuses of Valsalva). Family history was positive for sudden 
death in the proband’s oldest brother at the age of 26, for which the underlying etiology 
remained unconfirmed. This brother’s son was also affected, but no clinical information was 
available. The second brother of the proband was admitted to the emergency department at the 
age of 44 with an acute type A dissection extending to the abdominal aorta. Emergency 
surgery was successful, but was complicated by an inferior myocardial infarction. Pathology 
showed myxoid deposits in the intima, but no cystic media necrosis. The three children of this 
brother are all healthy. The proband’s father died at the age of 55 from an internal bleeding of 
unknown origin. His mother was healthy until old age. None of the patients showed any other 
connective tissue signs, except for livedo reticularis in the proband. 
 
Family 5 
The proband is a 14-year-old girl, who was referred to the genetics department after 
her mother’s sudden death from an acute type A aortic dissection during her third pregnancy. 
The proband was known with a patent ductus arteriosus but with normal aortic root 
measurements (26 mm at the sinuses of Valsalva; Z=0.87). Upon physical examination she 
presented mild skin translucency and joint hyperlaxity. Routine echocardiographic evaluation 
of her sister at the age of 6 years revealed mild dilatation at the sinuses of Valsalva (22mm, 
Z=2) and a small patent ductus arteriosus.  
 
Family 6  
The female proband was referred at the age of 27 because of a positive family history 
of aortic disease. Echocardiography showed normal aortic root and ascending aortic diameters 
but a CT-scan revealed a chronic type B aortic dissection originating at the left subclavian 
artery and extending to the renal arteries with a maximal diameter of 60mm at the descending 
thoracic aorta. She underwent surgical interposition of a Dacron conduit. Five years after 
surgery she developed a mild aneurysm at the left subclavian artery (1.3cm) and dilatation 
(4.3cm) of the native aorta (false lumen) in the descending aorta. Although her mother was 
asymptomatic, the proband’s maternal aunt had an extensive cardiovascular history. At the 
age of 20, she was diagnosed with mitral valve prolapse and ascending aortic dilatation 
progressing to an aneurysm requiring surgery at the age of 34. She is currently also under 
follow-up for an abdominal aortic aneurysm. The proband’s niece underwent aortic surgery at 
age 27 for a dissection of a thoraco-abdominal aneurysm. Her medical history also included 
profuse postpartum uterine hemorrhage and translucent skin with prominent subcutaneous 
vessels, easy bruising, early-onset varicose veins, small joint hypermobility, tendon/muscle 
rupture and atrophic scars, reminiscent of vascular Ehlers-Danlos syndrome. 
 
Family 7  
The 52-year-old male proband underwent a composite graft procedure because of an 
ascending aortic aneurysm with valvular insufficiency at the age of 29. At age 35, he 
presented with a dissection of the suprarenal abdominal aorta expanding to the superior 
mesenteric artery and with occlusion of the left common iliac artery. He is currently under 
follow-up for an enlarging ascending and arch aortic aneurysm distal from the prothesis. His 
father and paternal grandfather both died of aortic dissection between the age of 30 and 35, 
his brother suffered from a type A aortic dissection at age 35.   
 
Family 8  
The proband is a 36-year-old female, with a history of a PDA that was surgically 
corrected during childhood. Progressive aortic root dilatation was first noted at age 28 and 
treated with aortic root replacement at the age of 34. Clinical evaluation revealed no skeletal, 
ocular, skin or pulmonary problems. Her father suddenly died at the age of 63, probably from 
an aortic dissection. Her eldest sister underwent surgery for a PDA at the age of 12, and died 
suddenly at the age of 33. Autopsy revealed a type A aortic dissection extending in both 
carotid arteries and to the iliac bifurcation. Lungs showed minor emphysematous changes. 
Another sister died shortly after birth, probably due to congestive heart failure secondary to a 
PDA. Both other sisters are healthy, but the child of one of the sisters has severe pulmonary 
valve stenosis. The latter child’s paternal uncle had coronary artery disease at the age of 60. 
His 30-year-old daughter is currently in good general health, but had surgery at the age of 4 
for a severe pulmonary valve stenosis. 
 
All pedigrees are shown in Figure 2. Affected family members are indicated with a black box 
and the presence or absence of the mutation is indicated with a plus or minus sign, 
respectively.  
 
3.3 Immunohistochemistry of the aortic wall in patients with ACTA2 and MYH11 mutations 
The available aortic sections were co-stained with antibodies directed against smooth 
muscle α-actin and fibronectin-1 (FN1). Immunofluorescent FN1 staining showed well-
defined, intact FN fibrils and elastic fibers in aortic tissue in the control individuals, while the 
aortic tissue of MYH11- and ACTA2-mutation positive patients showed a marked 
fragmentation of the elastic fibers and a defective FN assembly in the tunica media. Smooth 
muscle α-actin staining was increased in MYH11-mutation positive tissues when compared to 
controls, indicating hyperproliferation of smooth muscle cells. Actin staining in aortic tissue 
from ACTA2 mutation-positive patients was variable. The morphology of the smooth muscle 
cells was also altered: patient aortic tissues from both ACTA2 and MYH11 mutation-positive 
patients showed the presence of few round shaped cells, while in the control tissues the 
majority of the smooth muscle cells were elongated (Figure 4).  
 
3.4 TGFβ signaling pathway 
In order to investigate alterations in TGFbeta signaling, all available aortic sections of 
patients and control individuals were stained for connective tissue growth factor (CTGF) and 
phospho-Smad2 (pSmad2). An increased intensity of staining for both proteins was seen in all 
family members with a MYH11 mutation as compared to the control tissues (only 1 family 
member is shown) (Figure 3). The staining intensity of CTGF and pSmad2 in the ACTA2 
mutation-positive patients was variable. Increased staining was seen in only one of the three 
aortic biopsies of the patients with an ACTA2 mutation, namely in patient II:4 from family 4 
with an ACTA2 missense mutation (only 1 out of 2 stainings of the patients with a premature 
termination codon is shown) (Figure 3). This finding suggests that upregulation of TGFβ 
signaling is involved in MYH11 pathogenesis and to a lesser extent in ACTA2 pathogenesis.  
4. Discussion 
Recent insights in the molecular basis of TAAD have shown the causal contribution of 
both MYH11 and ACTA2 mutations to the development of aortic aneurysms in at least a subset 
of patients [8-11]. In the present study, we therefore comprehensively screened both genes in 
a large cohort of patients with (familial) TAAD. While no MYH11 mutations were found in 
families with non-syndromic TAAD, we did identify a mutation in one out of two families 
associating TAAD with PDA. The MYH11 mutation-negative family was also negative for 
ACTA2. To our knowledge, this is the fifth MYH11 mutation reported to date and confirms 
that MYH11 mutations are rare and causal to this specific phenotype of TAAD associated with 
PDA. In contrast, we identified 7 ACTA2 mutations in the large cohort of 110 TAAD 
probands. A prevalence of 16% in patients with a positive family history indicates that ACTA2 
is mutated in a significant proportion of familial TAAD patients (7/43).  
At the molecular level, the MYH11 mutation (IVS32+1G>A) affects the canonical 
splice site sequence and is predicted to result in the loss of exon 32, and thus an in-frame 
deletion of 71 amino acids. This causes a conformational change of the α-helical coiled coil 
domain of the smooth muscle myosin heavy chain and impairs the motor function of the 
protein and its assembly with a homodimeric counterpart. This mutation is similar to the 
IVS32+1G>T mutation previously reported and further supports a dominant negative effect 
for MYH11 mutations [8]. 
All missense mutations in ACTA2 reported here affect highly conserved amino acids 
and result in a deleterious alteration of the 2nd subdomain surface, a domain important for the 
conformational change of actin upon the exchange of ADP for ATP, in its turn important in 
filament assembly dynamics [20]. A dominant negative mechanism with reduced assembly 
and incomplete and disorganized actin filament assembly was previously suggested for 
ACTA2 mutations [10]. The current study demonstrates for the first time that TAAD may also 
result from premature truncating mutations in ACTA2. However, both nonsense mutations are 
predicted to escape nonsense mediated decay and could as such still exert a dominant negative 
effect. This confirms the hypothesis formulated by Guo et al, who suggest that mutations 
resulting in true null alleles are inherited only with a recessive transmission pattern [10]. 
Possible limitations to the applied molecular studies are that both genes, ACTA2 and 
MYH11, were not tested for large deletions or insertions with Multiplex Ligation-dependent 
Probe Amplification (MLPA). Also, MLPA analysis for FBN1 and TGFBR1/2, was limited to 
a specific subset of patients with a high clinical suspicion for Marfan or Loeys-Dietz 
syndrome respectively (defined as patients presenting a TAA in addition to other 
characteristic clinical features of Marfan or Loeys-Dietz syndrome).  Screening of the recently 
identified TAAD causing genes SMAD3 and MYLK in the remaining cohort is ongoing. 
 
Both ACTA2 and MYH11 mutation-positive families reported so far display highly 
variable phenotypic expression with manifestations occurring at all age categories and not 
limited to the cardiovascular system [9, 11, 12, 16, 21]. The spectrum of clinical 
manifestations reported in this series is less extensive. More specifically, we did not observe 
significant manifestations of vasculo-occlusive disease nor of ocular, gastro-intestinal or 
urinary tract abnormalities, as reported by Milewicz et al [16]. One patient in our series 
presented livedo reticularis and we confirmed the presence of bicuspid aortic valve and patent 
ductus arteriosus in the clinical spectrum of the ACTA2 phenotype. There are several 
explanations possible for these discrepancies: firstly, it is very likely that we had a selection 
bias towards TAA since recruitment of patients and families occurred at a TAA reference 
centre (Centre for Medical Genetics, Ghent), secondly patients were clinically examined at 
different centers and no uniform vascular imaging protocol was used; subclinical vasculo-
occlusive disease cannot be excluded. Lastly, the relative small number of families described 
cannot exclude the presence of other clinical manifestations.   
Attempts have been made to identify genotype-phenotype correlations in ACTA2 
related disease. Guo et al suggested that the p.Arg258His mutation was primarily associated 
with stroke, PDA and Moya Moya disease, and p.Arg118Gln and p.Arg149Cys mutations 
were associated with Coronary Artery Disease (CAD) [11], but this has been refuted in 
subsequent studies [12, 14]. Supplemental table S1 shows no clear genotype-phenotype 
correlations in the majority of ACTA2 mutation-positive patients. 
Based on these observations regarding genotype-phenotype correlations, it seems 
likely that ACTA2 mutation related disease is similar to other heritable connective tissue 
disorders such as Marfan syndrome displaying a broad phenotypic spectrum that cannot be 
simply explained by the mutation characteristics. This suggests that other (environmental, 
epigenetic) factors may play a role and definitely merits further research. 
 
  The pathogenesis of TAAD caused by MYH11 or ACTA2 mutations remains 
intriguing but implicates a defective contractile apparatus. We observed a variable and 
increased smooth muscle α-actin staining in ACTA2 mutation-positive patients and MYH11 
mutation-positive patients, respectively. Moreover, aortic tissues of mutation-positive patients 
were characterized by the presence of a few round shaped, proliferating smooth muscle cells 
in the aortic media. These smooth muscle cells are thought not to produce contractile proteins 
in contrast to the elongated cells present in control tissues [22]. Nevertheless, these patients –
at least those with MYH11 mutation- show an increased smooth muscle α-actin staining, this 
contradictory finding might be explained by hyperproliferation of smooth muscle cells in the 
media as reported previously [10-12], rather than an increase in staining intensity of a single 
cell. In patients with an ACTA2 missense mutation as well as with a MYH11 mutation, we 
found direct evidence of increased TGFβ signaling in aortic tissue sections, as observed in 
syndromic forms of TAAD including Marfan syndrome, Loeys-Dietz syndrome and FBLN4 
and ELN-related cutis laxa [23-26]. This is in contrast with the previously reported 
experiments of Pannu and colleagues [9] that showed that there was no increased CTGF 
staining nor increased expression of CTGF and TGFβ1 in aortic tissue and smooth muscle 
cells of MYH11 patients. The precise contribution of TGFβ signaling to the pathogenesis of 
non-syndromic aortic aneurysms remains to be clarified [27]. Binding and contractility of the 
cytoskeleton via integrins is required for inducing a conformational change in fibronectin, 
allowing the association of fibronectin dimers into a stable insoluble fibrillar matrix (for a 
review see [28]). A stable fibronectin fibrillar matrix is in its turn indispensable for C-terminal 
association of fibrillin-1 monomers into bead-like structures and their linear assembly into 
microfibrils [29]. Furthermore, fibronectin microfibrils incorporate the large latent complex 
(TGFβ bound to its latency associated peptide, LAP, and latent TGFβ binding protein, LTBP) 
and transfer it to fibrillin-1 microfibrils which form the elastic fibers together with elastin [30-
33] (Figure 5A). Therefore, we hypothesize that increased TGFβ signaling could be explained 
by the fact that myosin or actin filaments that can no longer assemble correctly due to the 
presence of mutations in MYH11 or ACTA2, respectively, will result in a defective fibronectin 
fibril assembly at the cell surface, as seen in the fluorescent immunohistochemical staining 
(Figure 4). This in turn will lead to a defective fibrillin-1 assembly into microfibrils and will 
inhibit the sequestration of latent TGFβ, making it more prone to activation and leading to an 
increased amount of nuclear phosphorylated Smad2 and CTGF (Figure 5B). Further studies 
on the role of TGFβ signaling in ACTA2/MYH11 deficient patients are needed, as they could 
have a direct impact on the treatment options in these patients, such as the possibility of 
administrating losartan, a TGFβ antagonist to counteract the consequences of excess active 
TGFβ [34].  
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Legends to figures 
Figure 1 
Schematic overview of the ACTA2 (A,B) and MYH11 (C) protein. A. ACTA2 mutations 
previously described in the literature are marked in grey and the mutations we detected here 
are indicated in black. The numbers 1-9 indicate the exons. B. The ACTA2 mutations 
identified here (black) are mapped onto the crystal structure of actin (Protein Data Bank ID 
1LVT). C. MYH11 mutations previously described in literature are indicated in grey and the 
mutation described in this article is indicated in black. The grey amino terminal part of the 
schematic protein represents the myosin head-like domain with 1 ATP binding site and 2 
predicted actin binding sites, the black domain is the coiled-coil domain of the myosin heavy 
chain 11 protein.  
  
Figure 2  
Pedigrees of 7 families with ACTA2 mutation (family 1-7) and 1 family with MYH11 
mutation (family 8). Legend: black box = TAAD, arrow = proband, + = mutation present, - = 
mutation absent.  
 
Figure 3 
Immunohistochemical staining of aortic tissue in ACTA2 (c-f) and MYH11 (g-h) mutation-
positive patients and controls (a-b). Increased cytoplasmatic staining of CTGF and nuclear 
phospho-Smad2 accumulation is seen in the aortic tissue of patients with ACTA2 missense 
mutation (c and d, respectively) and MYH11 mutation (g and h, respectively) as compared to 
the control (a and b, respectively). No increase in CTGF nor pSmad2 staining is seen in the 
aortic tissue of a patient with ACTA2 nonsense mutation (e and f, respectively). 
 
Figure 4 
Immunofluorescent staining of aortic tissue in ACTA2 (e-l) and MYH11 (m-p) mutation-
positive patients and controls (a-d). Fragmented elastic fibers (FN1 - green) are seen in all 
patients (g,k,o) as compared to the control (c). Smooth muscle α-actin staining (red) is 
variable in ACTA2 mutation-positive patients (f,j) but seems to be increased in MYH11 
mutation-positive patients (n) in comparison to the control (b). Smooth muscle cells in the 
control tissues (b) had an elongated shape (indicated with an arrow), while aortic tissue from 
patients (f,j,n) showed the presence of few round shaped cells (indicated with an arrowhead). 
 
Figure 5 
Hypothetical model of the pathogenetic mechanism of MYH11 and ACTA2 mutations. A. 
Situation in healthy individuals: fibronectin assembly is initiated with the binding of 
fibronectin dimers onto an integrin receptor and syndecan, which possibly acts as a co-
receptor. Integrins and syndecan are also involved in assembly of the actin cytoskeleton. 
Fibronectin fibrillogenesis is promoted by the integrin/cytoskeleton complex by cell 
contractility, which induces conformational changes in fibronectin, allowing the association 
of multiple fibronectin molecules and formation of fibrils. Fibrillin-1 C-terminal association 
and formation of bead-like structures depends on these fibronectin fibrils. Fibronectin fibrils 
are also required for the sequestration of latent TGFβ, which is subsequently transferred onto 
the fibrillin-1 microfibrils, which are part of the elastic fibers. B. Mutations in MYH11 or 
ACTA2 will result in an incorrect assembly of the actin or myosin filaments, leading to a 
defect in fibronectin fibrillogenesis and resulting in an incorrect fibrillin-1 assembly into 
microfibrils and loss of the ability to sequestrate latent TGFβ. Latent TGFβ that is not 
incorporated into the matrix is more prone to activation and can bind to its receptors, initiating 
TGFβ signaling, characterized by phosphorylation of the receptor Smads (R-Smad), binding 
to the Co-Smad. This complex is then translocated to the nucleus and together with co-
regulators can initiate the transcription of target genes. Used abbreviations: TGFβR1 
(Transforming growth factor β receptor 1), TGFβR2 (Transforming growth factor β receptor 
2), R-Smad (Receptor Smad), FN (fibronectin), FBN1 (fibrillin-1), LLC (large latent complex 
= LTBP (latent TGFβ binding protein) + LAP (latency associated peptide) + TGFβ), SLC 
(small latent complex = LAP + TGFβ), TGFβ (Transforming growth factor β). 
